JP2012521353A - アルファ−（ｎ−ベンゼンスルホンアミド）シクロアルキル誘導体 - Google Patents
アルファ−（ｎ−ベンゼンスルホンアミド）シクロアルキル誘導体 Download PDFInfo
- Publication number
- JP2012521353A JP2012521353A JP2012500985A JP2012500985A JP2012521353A JP 2012521353 A JP2012521353 A JP 2012521353A JP 2012500985 A JP2012500985 A JP 2012500985A JP 2012500985 A JP2012500985 A JP 2012500985A JP 2012521353 A JP2012521353 A JP 2012521353A
- Authority
- JP
- Japan
- Prior art keywords
- compound
- mmol
- hydroxymethyl
- chloro
- benzenesulfonamide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 0 Cc1ccc(*)cc1 Chemical compound Cc1ccc(*)cc1 0.000 description 5
- MNGUPSDNPZROOY-JTHBVZDNSA-N CC([C@H](CCCC1)[C@@H]1N(Cc(c(F)c1)ccc1-c1ncc[o]1)S(c(cc1)ccc1Cl)(=O)=O)=O Chemical compound CC([C@H](CCCC1)[C@@H]1N(Cc(c(F)c1)ccc1-c1ncc[o]1)S(c(cc1)ccc1Cl)(=O)=O)=O MNGUPSDNPZROOY-JTHBVZDNSA-N 0.000 description 1
- AZPZBNBHYLIPGP-UHFFFAOYSA-N CNC(CC1CC2)C2C1O Chemical compound CNC(CC1CC2)C2C1O AZPZBNBHYLIPGP-UHFFFAOYSA-N 0.000 description 1
- PLVMXWDFKYDFNQ-BFUOFWGJSA-N C[C@H](CCCC1)[C@@H]1N(Cc(cc(c(-c1n[o]cn1)c1)F)c1F)S(c1ccc(C(F)(F)F)nc1)(=O)=O Chemical compound C[C@H](CCCC1)[C@@H]1N(Cc(cc(c(-c1n[o]cn1)c1)F)c1F)S(c1ccc(C(F)(F)F)nc1)(=O)=O PLVMXWDFKYDFNQ-BFUOFWGJSA-N 0.000 description 1
- QVICVEOQPSYKNC-SPLOXXLWSA-N C[C@H](CCCC1)[C@@H]1N(Cc(cc(c(C#N)c1)F)c1F)S(c(cc1)ccc1Cl)(=O)=O Chemical compound C[C@H](CCCC1)[C@@H]1N(Cc(cc(c(C#N)c1)F)c1F)S(c(cc1)ccc1Cl)(=O)=O QVICVEOQPSYKNC-SPLOXXLWSA-N 0.000 description 1
- KYJLSJMYBCZTFZ-UHFFFAOYSA-N O=S(c(cc1)ccc1Cl)=O Chemical compound O=S(c(cc1)ccc1Cl)=O KYJLSJMYBCZTFZ-UHFFFAOYSA-N 0.000 description 1
- LZUPDOPJRGUHOR-UHFFFAOYSA-N OC(C(CC1)C2)C1C2N(Cc(cc1)ccc1-c1ncc[o]1)S(c(cc1)ccc1Cl)(=O)=O Chemical compound OC(C(CC1)C2)C1C2N(Cc(cc1)ccc1-c1ncc[o]1)S(c(cc1)ccc1Cl)(=O)=O LZUPDOPJRGUHOR-UHFFFAOYSA-N 0.000 description 1
- KQJSZEDCGXNGKG-FIMBPPNMSA-N OC[C@H](CCCC1)[C@@]1(C1)[C@@H]1N(Cc(cc(c(-c1ncc[o]1)c1)F)c1F)S(c(cc1)ccc1Cl)(=O)=O Chemical compound OC[C@H](CCCC1)[C@@]1(C1)[C@@H]1N(Cc(cc(c(-c1ncc[o]1)c1)F)c1F)S(c(cc1)ccc1Cl)(=O)=O KQJSZEDCGXNGKG-FIMBPPNMSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D273/00—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00
- C07D273/02—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00 having two nitrogen atoms and only one oxygen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16185209P | 2009-03-20 | 2009-03-20 | |
| US61/161,852 | 2009-03-20 | ||
| PCT/US2010/027915 WO2010108067A1 (en) | 2009-03-20 | 2010-03-19 | Alpha-(n-benzenesulfonamido)cycloalkyl derivatives |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012521353A true JP2012521353A (ja) | 2012-09-13 |
| JP2012521353A5 JP2012521353A5 (enExample) | 2013-04-11 |
Family
ID=42235839
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012500985A Withdrawn JP2012521353A (ja) | 2009-03-20 | 2010-03-19 | アルファ−（ｎ−ベンゼンスルホンアミド）シクロアルキル誘導体 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US7977362B2 (enExample) |
| EP (1) | EP2408756B1 (enExample) |
| JP (1) | JP2012521353A (enExample) |
| CN (1) | CN102428074A (enExample) |
| WO (1) | WO2010108067A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100966705B1 (ko) | 2001-12-20 | 2010-06-29 | 브리스톨-마이어스 스큅 컴퍼니 | β-아밀로이드 저해제로서의α-(Ν-술폰아미도)아세트아미드 유도체 |
| US8044077B2 (en) | 2009-03-19 | 2011-10-25 | Bristol-Myers Squibb Company | Alpha-(N-sulfonamido)acetamide compounds incorporating deuterium as inhibitors of beta amyloid peptide production |
| US8252821B2 (en) | 2009-04-14 | 2012-08-28 | Bristol-Myers Squibb Company | Bioavailable capsule compositions of amorphous alpha-(N-sulfonamido)acetamide compound |
| EP2471363A1 (de) | 2010-12-30 | 2012-07-04 | Bayer CropScience AG | Verwendung von Aryl-, Heteroaryl- und Benzylsulfonamidocarbonsäuren, -carbonsäureestern, -carbonsäureamiden und -carbonitrilen oder deren Salze zur Steigerung der Stresstoleranz in Pflanzen |
| WO2013052700A1 (en) * | 2011-10-04 | 2013-04-11 | The Brigham And Women's Hospital, Inc. | Novel sulfonamides |
| WO2018108627A1 (de) | 2016-12-12 | 2018-06-21 | Bayer Cropscience Aktiengesellschaft | Verwendung substituierter indolinylmethylsulfonamide oder deren salze zur steigerung der stresstoleranz in pflanzen |
| WO2019025153A1 (de) | 2017-07-31 | 2019-02-07 | Bayer Cropscience Aktiengesellschaft | Verwendung von substituierten n-sulfonyl-n'-aryldiaminoalkanen und n-sulfonyl-n'-heteroaryldiaminoalkanen oder deren salzen zur steigerung der stresstoleranz in pflanzen |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5274094A (en) | 1990-08-15 | 1993-12-28 | British Bio-Technology Limited | Production of heterobicyclic containing benzene sulfonamides |
| GB9202791D0 (en) | 1992-02-11 | 1992-03-25 | British Bio Technology | Compounds |
| US5583221A (en) | 1994-05-04 | 1996-12-10 | Eli Lilly And Company | Substituted fused and bridged bicyclic compounds as therapeutic agents |
| DK0874836T3 (da) | 1995-11-17 | 2003-02-10 | Warner Lambert Co | Sulfonamidinhibitorer af matrix metalloproteinaser |
| PL331338A1 (en) | 1996-07-22 | 1999-07-05 | Monsanto Co | Thiosulphonamidic metaloprotease inhibitors |
| JPH11343279A (ja) | 1998-03-16 | 1999-12-14 | Shionogi & Co Ltd | スルホンアミド誘導体およびそれらを含有するＴＮＦ―α産生抑制剤 |
| EP1149074B1 (en) | 1999-01-27 | 2004-10-20 | Wyeth Holdings Corporation | Acetylenic sulfonamide thiol tace inhibitors |
| US6313123B1 (en) | 1999-01-27 | 2001-11-06 | American Cyanamid Company | Acetylenic sulfonamide thiol tace inhibitors |
| CN1348442A (zh) | 1999-02-26 | 2002-05-08 | 默克公司 | 新的磺胺化合物及其应用 |
| KR100966705B1 (ko) | 2001-12-20 | 2010-06-29 | 브리스톨-마이어스 스큅 컴퍼니 | β-아밀로이드 저해제로서의α-(Ν-술폰아미도)아세트아미드 유도체 |
| EP1608638A1 (en) | 2003-03-31 | 2005-12-28 | Wyeth | Fluoro-and trifluoroalkyl-containing heterocyclic sulfonamide inhibitors of beta amyloid production and derivatives thereof |
| AU2004285022A1 (en) * | 2003-10-29 | 2005-05-12 | Elan Pharmaceuticals, Inc. | N-substituted benzene sulfonamides |
| US7163942B2 (en) | 2004-04-01 | 2007-01-16 | Pfizer Inc. | Sulfonamide compounds for the treatment of neurodegenerative disorders |
| CA2573372A1 (en) * | 2004-07-13 | 2006-01-19 | F. Hoffmann-La Roche Ag | Sulfonamide derivatives |
| US7144894B2 (en) | 2004-09-23 | 2006-12-05 | Bristol-Myers Squibb Company | Sulfonamide bicyclic compounds |
| CA2637615A1 (en) | 2006-02-17 | 2007-08-30 | Wyeth | Selective n-sulfonylation of 2-amino trifluoroalkyl substituted alcohols |
| PE20080169A1 (es) | 2006-02-17 | 2008-04-11 | Wyeth Corp | Metodo para preparar alcoholes sustituidos con sulfonamidas y sus compuestos intermedios |
| WO2008112249A1 (en) | 2007-03-13 | 2008-09-18 | Trustees Of Columbia University In The City Of New York | Synergistic interaction of notch-1 inhibitors with glucocorticoids |
| WO2009005688A2 (en) | 2007-06-29 | 2009-01-08 | Trustees Of Columbia University In The City Of New York | Activating mutations in notch-1 |
| US8084477B2 (en) | 2007-10-31 | 2011-12-27 | Bristol-Myers Squibb Company | Alpha-(N-sulfonamido)acetamide compound as an inhibitor of beta amyloid peptide production |
| CN102088855A (zh) | 2008-05-08 | 2011-06-08 | 百时美施贵宝公司 | 2-芳基甘氨酰胺衍生物 |
| US8044077B2 (en) | 2009-03-19 | 2011-10-25 | Bristol-Myers Squibb Company | Alpha-(N-sulfonamido)acetamide compounds incorporating deuterium as inhibitors of beta amyloid peptide production |
| KR20110133046A (ko) | 2009-03-19 | 2011-12-09 | 브리스톨-마이어스 스큅 컴퍼니 | 베타 아밀로이드 펩티드 생성의 억제제로서의 신규 알파-(ｎ-술폰아미도)아세트아미드 화합물 |
| US20110071199A1 (en) | 2009-03-20 | 2011-03-24 | Bristol-Myers Squibb Company | Thiophenyl Sulfonamides for the Treatment of Alzheimer's Disease |
| US8252821B2 (en) | 2009-04-14 | 2012-08-28 | Bristol-Myers Squibb Company | Bioavailable capsule compositions of amorphous alpha-(N-sulfonamido)acetamide compound |
| TW201043269A (en) | 2009-04-14 | 2010-12-16 | Bristol Myers Squibb Co | Bioavailable compositions of amorphous alpha-(N-sulfonamido)acetamide compound |
-
2010
- 2010-03-17 US US12/725,810 patent/US7977362B2/en active Active
- 2010-03-19 JP JP2012500985A patent/JP2012521353A/ja not_active Withdrawn
- 2010-03-19 CN CN2010800222929A patent/CN102428074A/zh active Pending
- 2010-03-19 EP EP10709946.7A patent/EP2408756B1/en not_active Not-in-force
- 2010-03-19 WO PCT/US2010/027915 patent/WO2010108067A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| EP2408756A1 (en) | 2012-01-25 |
| US20100240708A1 (en) | 2010-09-23 |
| US7977362B2 (en) | 2011-07-12 |
| EP2408756B1 (en) | 2013-05-15 |
| CN102428074A (zh) | 2012-04-25 |
| WO2010108067A1 (en) | 2010-09-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5460605B2 (ja) | βアミロイドペプチド産生の阻害剤としての新規α−（Ｎ−スルホンアミド）アセトアミド化合物 | |
| EP2408756B1 (en) | Alpha-(n-benzenesulfonamido)cycloalkyl derivatives | |
| US7659294B2 (en) | 2-(aryl)azacyclylmethyl carboxylates, sulfonates, phosphonates, phosphinates and heterocycles as S1P receptor agonists | |
| JP2005531506A (ja) | Ｅｄｇ受容体作動薬としてのアミノアルキルホスホネートおよび関連化合物 | |
| JP2005531508A (ja) | Ｅｄｇ受容体作動薬としてのアミノアルキルホスホネートおよび関連化合物 | |
| CN103338764A (zh) | 作为鞘氨醇1-磷酸(s1p)受体调节剂的新型氮杂环丁烷衍生物 | |
| EP2408757B1 (en) | A novel alpha-(n-sulfonamido) acetamide compound incorporating deuterium as inhibitor of beta amyloid peptide production | |
| EP2408760A1 (en) | Thiophenyl sulfonamides for the treatment of alzheimer's disease | |
| CA2879236A1 (en) | Mineralocorticoid receptor antagonists | |
| EP2408450B1 (en) | Alpha-(n-sulfonamido)acetamide compound as an inhibitor of beta amyloid peptide production | |
| US8093276B2 (en) | Alpha-(N-sulfonamido)acetamide compound as an inhibitor of beta amyloid peptide production | |
| HK1141801B (en) | A novel alpha-(n-sulfonamido)acetamide compound as an inhibitor of beta amyloid peptide production |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130220 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20130220 |
|
| A761 | Written withdrawal of application |
Free format text: JAPANESE INTERMEDIATE CODE: A761 Effective date: 20130628 |